Zusammenfassung
Aufgrund der Alterung der Bevölkerung nimmt die Prävalenz der Aortenklappenstenose deutlich zu. Da die Überlebensraten bei konservativer Therapie schlecht sind, aber 33% der Patienten mit signifikanter symptomatischer Aortenstenose einer Operation nicht zugeführt werden, ist eine Alternative zum chirurgischen Klappenersatz wünschenswert. Ist aufgrund der Verbreitung des transkutanen kathetergestützten Aortenklappenersatzes (TAVI), der DRG-Erstattung und der Empfehlung zu ihrer Anwendung durch Positionspapiere der kardiologischen Gesellschaften das Verfahren bereits etabliert? Wenn wir Heil- oder Behandlungsverfahren erst dann als etabliert ansehen, wenn sie einen Nutzen erbringen, notwendig und wirtschaftlich sind, dann ergeben sich allerdings aufgrund mangelnder Daten zum Nutzen und zur Wirtschaftlichkeit für das TAVI-Verfahren Zweifel, und wir können TAVI als nicht etabliert ansehen.
Abstract
Western countries are facing a huge increase of hemodynamically relevant cases of aortic stenosis in an aging population. In the past, about 33% of patients with symptomatic aortic stenosis were not referred for aortic valve replacement although the three years survival rate is only 25 percent after conservative treatment. In Germany transcatheter aortic-valve implantations (TAVI) procedures are reimbursed according to a DRG number. Its usage its not only regulated in a position paper of the German Society of Cardiology giving detailed recommendations for its application and indication. In Germany, approximately 4.000 TAVI procedures were performed in 2009 and even more are expected in 2010. According to the frequency of its usage, DRG reimbursement, and position papers, TAVI procedures seem to be established. However, according to health regulations a new treatment modality is only established if its safety and efficiency is proven, if there is a demand, and if the procedure has economic advantages. According to this definition TAVI is not established since its safety and efficiency compared to the surgical treatment was not been proven in randomised trials yet. Its economic burden in this context is unclear, too. However, there is a need for an alternative to surgical aortic valve replacement to increase the acceptance of valve implantation in an aging population.
Literatur
Nkomo VT, Gardin JM, Skelton TN et al (2006) Burden of valvular heart diseases: a population-based study. Lancet 368:1005–1011
O’Keefe JH, Vlietstra RE, Bailey KR et al (1987) Natural history of candidates for balloon aortic valvuloplasty. Mayo Clin Proc 62:986–991
Cribier A, Eltchaninoff H, Bash A et al (2002) Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation 106:3006–3008
Leon MB, Smith CR, Mack M et al (2010) Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J 363(17):1597–1607
Bekkering GE, Kleijnen J (2008) Procedures and methods of benefit assessments for medicines in Germany. Eur J Health Econ 9(Suppl 1):5–29
Piazza N, Grube E, Gerckens U et al (2008) Procedural and 30-day outcomes following transcatheter aortic valve implantation using the third generation (18 F) CoreValve ReValving system: results from the multicentre, expanded evaluation registry 1-year following CE mark approval. EuroIntervention 4:242–249
Zahn R, Gerckens U, Grube E et al (2010) Transcatheter aortic valve implantation: first results from a multi-centre real-world registry. Eur Heart J 32(2):198–204
Zahn R (2010) Deutsches Aortenklappenregister. Vortrag EuroPCR Paris
Iung B, Cachier A, Baron G et al (2005) Decision-making in elderly patients with severe aortic stenosis: why are so many denied surgery? Eur Heart J 26:2714–2720
Rogowski WH, Landauer M, John J (2009) Entscheidungsanalytische Modellierung von Kosten pro QALY im Kontext des deutschen Sozialrechts. Gesundheitswesen 71:739–750
Figulla HR, Cremer J, Walther T et al (2009) Positionspapier zur kathetergeführten Aortenklappenintervention. Kardiologe 3:199–206
Figulla HR, Ferrari M (2006) Percutaneous implantable aortic valve: the JenaValve concept evolution. Herz 31:685–687
Sacks S, Schofer J (2009) Transcatheter aortic valve implantation. Present and future technologies. Herz 34:357–366
Al-Attar N, Nataf P (2009) Development of aortic valve implantation. Herz 34:367–373
Interessenkonflikt
Der korrespondierende Autor weist auf folgende Beziehungen hin: Gründer und Anteilseigner bei der Firma JenaValve, München.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Figulla, H., Ferrari, M. Kathetergeführte Aortenklappenimplantation. Herz 36, 116–120 (2011). https://doi.org/10.1007/s00059-011-3421-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00059-011-3421-z
Schlüsselwörter
- Transkutane kathetergestütze Aortenklappenimplantation(TAVI)
- Aortenklappenstenose
- Kosten-Nutzen-Analyse